title: Anticipating a Vioxx defense strategy: will corporate honesty be enough?
authors.affiliation: Godwin Pappas Langley Ronquillo, LLP, Dallas, Texas USA. kwillis@godwinpappas.com
authors.forename: Kirk D
authors.initials: KD
authors.lastname: Willis
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D003257:Consumer Product Safety; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D040861:Ethics, Business; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones